Monday, July 15, 2024

AstraZeneca reaffirms its dedication to safeguarding high-risk individuals from severe infectious illnesses during IDWeek 2023

Similar articles

AstraZeneca is set to present vital data from its Vaccines & Immune Therapies portfolio at the upcoming 12th annual IDWeek conference. The data underscores the critical role of long-acting antibodies and vaccines in protecting high-risk individuals from common infectious respiratory diseases. The presentations will cover several key aspects:

  1. Real-World Evidence for COVID-19: AstraZeneca will present real-world data demonstrating the ongoing and disproportionate burden of COVID-19 on immunocompromised individuals. The findings highlight the urgent need for additional protection measures for this vulnerable group.
  2. Beyfortus (nirsevimab): This long-acting antibody designed to prevent disease due to respiratory syncytial virus (RSV) will be featured, showcasing its role in safeguarding high-risk individuals from RSV.
  3. Self-Administration of FluMist Quadrivalent: AstraZeneca will discuss the potential for self-administered intranasal influenza vaccines, focusing on expanding access to this preventive tool. This approach aims to make seasonal influenza vaccines more accessible to a broader population.
  4. AZD3152: This is an investigational long-acting antibody designed to counter COVID-19. The presentation will provide updated data on AZD3152’s effectiveness against various COVID-19 variants.

The overarching theme is the protection of at-risk individuals from infectious respiratory diseases. It highlights the need to ensure that no one, especially the immunocompromised, is left behind when it comes to safeguarding against these infections. The data reinforces the importance of long-acting antibodies and vaccines in achieving this goal.

Furthermore, the data underscores the ongoing and substantial burden of COVID-19 on immunocompromised individuals, even when they are fully vaccinated. The findings emphasize the necessity of tailored protection measures for this vulnerable population.

In terms of influenza prevention, the potential for self-administration of the FluMist Quadrivalent intranasal vaccine is explored as a means to improve vaccine accessibility, especially for underserved communities. This approach aligns to increase vaccination rates and reduce the impact of influenza.

AstraZeneca’s comprehensive presentations aim to advance the understanding of how long-acting antibodies and innovative vaccination methods can better protect those most susceptible to infectious respiratory diseases.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article